Wednesday, 26 August 2026European Markets

MYHOTELMATCH Stock Bearish Momentum With A 28% Fall In The Last 10 Sessions

Loading stream...

(vianews) - shares of myhotelmatch (cac 40: mhm.pa) slid by a staggering 28.06% in 10 sessions from €0.03 to €0.02 at 23:06 est on friday, after five consecutive sessions in a row of losses. cac 40 is dropping 0.55% to €7,163.42, after four sequential sessions in a row of losses.

myhotelmatch's last close was €0.02, 40.72% under its 52-week high of €0.04.

about myhotelmatch

myhotelmatch s.a. engages in the development and exploitation of an online hotel reservation platform based on artificial intelligence (ai). it operates as an online travel agency based on the principle of online dating. the company, through its platform, connect a traveler and hotels with online hotel services whose profiles match. the company is based in biot, france.

earnings per share

as for profitability, myhotelmatch has a trailing twelve months eps of €-0.04.

yearly top and bottom value

myhotelmatch's stock is valued at €0.02 at 23:06 est, way below its 52-week high of €0.04 and way above its 52-week low of €0.01.

volume

today's last reported volume for myhotelmatch is 2906185 which is 21.76% below its average volume of 3308360.

volatility

myhotelmatch's last week, last month's, and last quarter's current intraday variation average was a negative 2.16%, a negative 1.06%, and a positive 5.36%.

myhotelmatch's highest amplitude of average volatility was 2.16% (last week), 4.60% (last month), and 5.36% (last quarter).

more news about myhotelmatch (mhm.pa).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
AI Leadership Exodus Rattles Investor Confidence Amid Capex Boom
High-profile departures at top AI labs — Brad Lightcap's exit from OpenAI and an unnamed researcher's departure from Alphabet/Google that triggered a share-price drop — are surfacing talent retention as a market risk factor even as hyperscalers pour record capital into AI infrastructure. The reaction shows investors treating key-person risk at frontier AI labs as material to valuation, a new fragility layered onto an otherwise bullish AI-driven capex cycle.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Broadcom Inc.
Both facts report EPS for Broadcom Inc. for the same fiscal period (Q1 2026) observed on the same date (2026-02-01). However, they report conflicting values: 1.5 USD per share vs 2.05 USD per share. This is a 37% difference for the identical metric and time period, not a value change over time.
We flag conflicts openly ›
Recently verified
Checked against the original source
4,978
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,978 facts checked against source5,251 source documents archived
Query this data → isubstrate.com